Opinion|Videos|November 6, 2024
Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis
Key Takeaways
- Combination therapy in gMG is used for patients with severe symptoms or inadequate response to monotherapy, enhancing treatment efficacy.
- Targeted treatments have revolutionized the management of newly diagnosed gMG patients, enabling more personalized therapeutic strategies.
Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.
Advertisement
Video content above is prompted by the following:
- Phase 3 data of nipocalimab, an FcRn inhibitor, has recently been presented at the European Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine conferences in 2024. Please review the efficacy and safety data for nipocalimab in different patient populations.
- What do phase 3 results add to phase 2 study findings with nipocalimab?
- What are your thoughts about nipocalimab data for generalized myasthenia gravis (gMG)?
- Please review the recently published data from the phase 3 trial of investigational FcRn inhibitor batoclimab for gMG.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5